Patients with chronic obstructive pulmonary disease (COPD) often suffer acute exacerbations (AECOPD) and community-acquired pneumonia (CAP), named nonpneumonic and pneumonic exacerbations of COPD, respectively. Abnormal host defense mechanisms may play a role in the specificity of the systemic inflammatory response. Given the association of this aspect to some biomarkers at admission (e.g., C-reactive protein), it can be used to help to discriminate AECOPD and CAP, especially in cases with doubtful infiltrates and advanced lung impairment. Fever, sputum purulence, chills, and pleuritic pain are typical clinical features of CAP in a patient with COPD, whereas isolated dyspnea at admission has been reported to predict AECOPD. Although CAP may have a worse outcome in terms of mortality (in hospital and short term), length of hospitalization, and early readmission rates, this has only been confirmed in a few prospective studies. There is a lack of methodologically sound research confirming the impact of severe AECOPD and COPD + CAP. Here, we review studies reporting head-to-head comparisons between AECOPD and CAP + COPD in hospitalized patients. We focus on the epidemiology, risk factors, systemic inflammatory response, clinical and microbiological characteristics, outcomes, and treatment approaches. Finally, we briefly discuss some proposals on how we should orient research in the future.

Pneumonic versus Nonpneumonic Exacerbations of Chronic Obstructive Pulmonary Disease / Crisafulli, E; Manco, A; Ferrer, M; Huerta, A; Micheletto, C; Girelli, D; Clini, E; Torres, A.. - In: SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE. - ISSN 1069-3424. - 41:6(2020), pp. 817-829. [10.1055/s-0040-1702196]

Pneumonic versus Nonpneumonic Exacerbations of Chronic Obstructive Pulmonary Disease.

Clini, E;
2020

Abstract

Patients with chronic obstructive pulmonary disease (COPD) often suffer acute exacerbations (AECOPD) and community-acquired pneumonia (CAP), named nonpneumonic and pneumonic exacerbations of COPD, respectively. Abnormal host defense mechanisms may play a role in the specificity of the systemic inflammatory response. Given the association of this aspect to some biomarkers at admission (e.g., C-reactive protein), it can be used to help to discriminate AECOPD and CAP, especially in cases with doubtful infiltrates and advanced lung impairment. Fever, sputum purulence, chills, and pleuritic pain are typical clinical features of CAP in a patient with COPD, whereas isolated dyspnea at admission has been reported to predict AECOPD. Although CAP may have a worse outcome in terms of mortality (in hospital and short term), length of hospitalization, and early readmission rates, this has only been confirmed in a few prospective studies. There is a lack of methodologically sound research confirming the impact of severe AECOPD and COPD + CAP. Here, we review studies reporting head-to-head comparisons between AECOPD and CAP + COPD in hospitalized patients. We focus on the epidemiology, risk factors, systemic inflammatory response, clinical and microbiological characteristics, outcomes, and treatment approaches. Finally, we briefly discuss some proposals on how we should orient research in the future.
2020
29-lug-2020
41
6
817
829
Pneumonic versus Nonpneumonic Exacerbations of Chronic Obstructive Pulmonary Disease / Crisafulli, E; Manco, A; Ferrer, M; Huerta, A; Micheletto, C; Girelli, D; Clini, E; Torres, A.. - In: SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE. - ISSN 1069-3424. - 41:6(2020), pp. 817-829. [10.1055/s-0040-1702196]
Crisafulli, E; Manco, A; Ferrer, M; Huerta, A; Micheletto, C; Girelli, D; Clini, E; Torres, A.
File in questo prodotto:
File Dimensione Formato  
Crisafulli (Pneumonic vs non-Pneumonic AECOPD- review 2020).pdf

Accesso riservato

Tipologia: Versione pubblicata dall'editore
Dimensione 212.74 kB
Formato Adobe PDF
212.74 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1207673
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 4
  • ???jsp.display-item.citation.isi??? 5
social impact